Immunome Financial Ratios
NASDAQ: IMNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
19.55+0.24 (+1.24%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunome ratio analysis
Immunome earned a net margin of -3060.0% in FY 2025, up from -3240.4% a year earlier. Return on equity reached -33.5%, meaning Immunome generated -0.33 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Immunome financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Price / sales | 262.02 | 73.10 | 15.15 | — | — | — | — |
| Price / book | 2.87 | 3.65 | 1.77 | 1.61 | 3.10 | 0.79 | — |
| Operating margin | -3,228.8% | -3,382.4% | -781.4% | — | — | — | — |
| Net margin | -3,060.0% | -3,240.4% | -761.9% | — | — | — | — |
| Free cash flow margin | -2,890.1% | -1,304.8% | -59.9% | — | — | — | — |
| Return on equity (ROE) | -33.5% | -161.7% | -89.1% | -221.6% | -51.3% | -43.1% | — |
| Return on assets (ROA) | -31.1% | -121.9% | -71.9% | -153.4% | -42.7% | -40.1% | -206.4% |
| Debt / equity | — | — | — | — | — | 0.01 | — |
| Current ratio | 14.69 | 4.08 | 6.63 | 3.09 | 5.82 | 14.12 | 1.88 |
| Revenue growth | -23.2% | -35.5% | — | — | — | — | — |